D-penicillamine-induced granulomatous hepatitis in brown Norway rats.
The mechanism of idiosyncratic drug reactions (IDRs) remains poorly understood. D-penicillamine treatment is associated with a wide range of autoimmune reactions including liver injury. An animal model which utilizes brown Norway (BN) rats has been used to investigate the mechanism of D-penicillamine-induced IDRs because it mimics the autoimmune reactions that occur in humans. The purpose of this study was to investigate the type of liver injury that results from D-penicillamine treatment in BN rats. We had previously noted that D-penicillamine caused histological changes in the liver, but there was no increase in alanine transaminase (ALT), and we assumed that there was no significant injury. However, we subsequently discovered that D-penicillamine inhibits the ALT assay. In the present study, we found that treatment of BN rats with a low doses of D-penicillamine (10 or 15 mg/day) resulted in a mild increases in glutamate dehydrogenase (GLDH) and sorbitol dehydrogenase (SDH) activities; however, this was not associated with histological changes. A higher dose of D-penicillamine (20 mg/day) resulted in 63% of the rats developing a skin rash, and these rats had elevated serum GLDH and SDH levels with histopathological changes characteristic of granulomatous hepatitis. This included large clusters of leukocytes in the form of granulomas that contained neutrophils, macrophages, and CD8 T cells. These changes did not occur in the rats that did not get sick. This model may be a good model to investigate the characteristics of drug-induced granulomatous hepatitis.
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada, imir.metushi@mail.utoronto.ca.
Imir G
IG
Metushi
Xu
X
Zhu
Jack
J
Uetrecht
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001327:Autoimmune Diseases; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects; D056486:Chemical and Drug Induced Liver Injury / Q000097:blood* / Q000473:pathology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000378:metabolism* / Q000473:pathology; D005076:Exanthema / Q000139:chemically induced / Q000378:metabolism*; D005969:Glutamate Dehydrogenase / Q000097:blood; D006801:Humans; D007064:L-Iditol 2-Dehydrogenase / Q000097:blood; D023421:Models, Animal; D010396:Penicillamine / Q000633:toxicity*; D051381:Rats
D007064:L-Iditol 2-Dehydrogenase; D005969:Glutamate Dehydrogenase; D000410:Alanine Transaminase; D010396:Penicillamine